1Narayanan SN, Ahamed MZ, Safia M. Cardiovascular involvement in Kawasaki disease[J]. Indian Pediatr, 2005,42 (9) : 918-922.
2Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition)[J]. Pediatr Int, 2005,47 (2) : 232-234.
3Nomura Y, Masuda K, Maeno N, et al. Serum levels of intefleukin18 are elevated in the subacute phase of kawasaki syndrome [J]. Int Arch Allergy Immunol, 2004,135 (2) : 161-165.
5Tsai MH,Huang YC,Yen MH,et al. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin[J]. J Pediatr, 2006,148( 1 ) : 38-43.
2Rowley AH,Shulman ST.Kawasaki syndrome[J].Pediatr Clin North Am,1999,46(2):313-329.
3Kato H,Sugimura T,Akagi T,et al.Long-termconsequences of Kawasaki disease:a 10-to 21-year follow-up study of 594 patients[J].Circulation,1996,94 (6):1379-1385.
4Terai M,Shulman ST.Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independendent of salicylate dose[J].J Pediatr,1997,131(6):888 -893.
3Miura M,Sugiura T, Aimi Y, et al.Effects ofulinastatin on PMNL and vascular endothelial injury in patients undergoing open heart surgerywith CPB[J].Masu I,1998;47(1):29-32.
4Zaitsu M,Hamasaki Y, Tashiro K,et al.Ulinastatin,an elastase inhibitor, inhibits the increased mRNA expression of prostagland H2 synthase-type 2 in Kawasaki disease[J].J Infect Dis,2000; 181 (3): 1101-1109.
